Skip to main content

The Legacy Builders Young Investigator Grant

Project Title

Aberrant BER confers sensitivity to PARP Inhibitors in pediatric AML

Layman’s summary

Despite overall cure rates of pediatric cancer reaching nearly 80%, the overall survival of children diagnosed with acute myeloid leukemia (AML) is approximately 60%. This study evaluates a drug commonly used in breast cancer called a PARP inhibitor in pediatric patients with relapsed AML. It seeks to exploit faults in DNA repair and identify those patients with cancers where these faults are present so that we can provide targeted treatment and improve outcomes for these patients.

Jennifer Kamens

This Project By The Numbers

  • Years Active
    3 Years
  • Amount Awarded
  • Institution
    Stanford University